Literature DB >> 23812730

HtrA3 is negatively correlated with lymph node metastasis in invasive ductal breast cancer.

Yongxiang Yin1, Man Wu, Guiying Nie, Ke Wang, Jia Wei, Min Zhao, Qi Chen.   

Abstract

Breast cancer is the most common cancer in women worldwide. Studies have shown that the high temperature requirement factor A3 (HtrA3) is involved in important physiological processes including maintenance of mitochondrial homeostasis, cell death, and cell signaling. HtrA3 is reported to be downregulated in several cancers and has been correlated with advancing cancer stage. We performed a retrospective study using our breast cancer tissue bank to investigate whether the expression of HtrA3 correlated with lymphatic metastasis in breast cancer and whether the expression of HtrA3 was correlated with estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer. Breast cancer tissues from 156 invasive ductal breast cancer patients with or without lymphatic metastasis were collected and the levels of HtrA3 were measured by immunohistochemistry and western blotting. The expression of HtrA3 was lower in breast cancer. In particular, HtrA3 expression in breast cancer with lymphatic metastasis was lower than that in breast cancer without lymphatic metastasis. In breast cancers with no lymphatic metastasis, the expression of HtrA3 was lower in patients with ER- and PR-positive tumors, but when breast cancers with lymphatic metastasis were analyzed, there was no difference in HtrA3 expression between ER- and PR-positive or ER- and PR-negative tumors. These data suggest that the expression of HtrA3 was negatively correlated with lymphatic metastasis in breast cancer but not correlated with ER and PR positivity or negativity. A better understanding of the mechanism of HtrA3 may provide the basis for future development of a novel therapeutic target in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812730     DOI: 10.1007/s13277-013-0942-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

Review 1.  Targeting the TGF beta signaling network in human neoplasia.

Authors:  Nancy Dumont; Carlos L Arteaga
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

2.  Inhibition of HTRA3 stimulates trophoblast invasion during human placental development.

Authors:  H Singh; S-i Makino; Y Endo; G Nie
Journal:  Placenta       Date:  2010-10-29       Impact factor: 3.481

Review 3.  HTRA proteases: regulated proteolysis in protein quality control.

Authors:  Tim Clausen; Markus Kaiser; Robert Huber; Michael Ehrmann
Journal:  Nat Rev Mol Cell Biol       Date:  2011-02-16       Impact factor: 94.444

4.  Primary structure of a putative serine protease specific for IGF-binding proteins.

Authors:  J Zumbrunn; B Trueb
Journal:  FEBS Lett       Date:  1996-12-02       Impact factor: 4.124

Review 5.  Overview of resistance to systemic therapy in patients with breast cancer.

Authors:  Ana Maria Gonzalez-Angulo; Flavia Morales-Vasquez; Gabriel N Hortobagyi
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

6.  Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer.

Authors:  Marissa A Bowden; Lisa A Di Nezza-Cossens; Tom Jobling; Lois A Salamonsen; Guiying Nie
Journal:  Gynecol Oncol       Date:  2006-05-02       Impact factor: 5.482

Review 7.  HtrA serine proteases as potential therapeutic targets in cancer.

Authors:  Jeremy Chien; Mara Campioni; Viji Shridhar; Alfonso Baldi
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

8.  Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-beta signaling.

Authors:  Jiraporn Tocharus; Akiho Tsuchiya; Miwa Kajikawa; Yoshifumi Ueta; Chio Oka; Masashi Kawaichi
Journal:  Dev Growth Differ       Date:  2004-06       Impact factor: 2.053

9.  Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer.

Authors:  Joanna Narkiewicz; Sylwia Lapinska-Szumczyk; Dorota Zurawa-Janicka; Joanna Skorko-Glonek; Janusz Emerich; Barbara Lipinska
Journal:  Oncol Rep       Date:  2009-06       Impact factor: 3.906

10.  Micrometastases or isolated tumor cells and the outcome of breast cancer.

Authors:  Maaike de Boer; Carolien H M van Deurzen; Jos A A M van Dijck; George F Borm; Paul J van Diest; Eddy M M Adang; Johan W R Nortier; Emiel J T Rutgers; Caroline Seynaeve; Marian B E Menke-Pluymers; Peter Bult; Vivianne C G Tjan-Heijnen
Journal:  N Engl J Med       Date:  2009-08-13       Impact factor: 91.245

View more
  5 in total

1.  OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.

Authors:  Michael Rose; Claudia Schubert; Laura Dierichs; Nadine T Gaisa; Matthias Heer; Axel Heidenreich; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

2.  High temperature requirement A3 (HTRA3) expression predicts postoperative recurrence and survival in patients with non-small-cell lung cancer.

Authors:  Jingya Zhao; Jing Zhang; Xin Zhang; Mingxiang Feng; Jieming Qu
Journal:  Oncotarget       Date:  2016-06-28

3.  Long intergenic non‑coding RNA 00467 promotes lung adenocarcinoma proliferation, migration and invasion by binding with EZH2 and repressing HTRA3 expression.

Authors:  Xianghai Wang; Hongbing Liu; Kaikai Shen; Xianhui Pan; Yuqing Wei; Tangfeng Lv; Yong Song
Journal:  Mol Med Rep       Date:  2019-05-23       Impact factor: 2.952

4.  Maternal HtrA3 optimizes placental development to influence offspring birth weight and subsequent white fat gain in adulthood.

Authors:  Ying Li; Lois A Salamonsen; Jonathan Hyett; Fabricio da Silva Costa; Guiying Nie
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

5.  Transcriptional landscape of the embryonic chicken Müllerian duct.

Authors:  Zahida Yesmin Roly; Rasoul Godini; Martin A Estermann; Andrew T Major; Roger Pocock; Craig A Smith
Journal:  BMC Genomics       Date:  2020-10-02       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.